Squarepoint’s Kronos Bio KRON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-113,607
Closed -$93.7K 4782
2025
Q1
$93.7K Buy
113,607
+15,187
+15% +$14.6K ﹤0.01% 4235
2024
Q4
$93.5K Buy
+98,420
New +$92.9K ﹤0.01% 4712
2024
Q2
Sell
-107,754
Closed -$140K 4379
2024
Q1
$140K Sell
107,754
-45,668
-30% -$52.1K ﹤0.01% 3722
2023
Q4
$192K Buy
153,422
+18,539
+14% +$20.5K ﹤0.01% 3611
2023
Q3
$175K Sell
134,883
-90,777
-40% -$147K ﹤0.01% 3451
2023
Q2
$388K Buy
225,660
+179,572
+390% +$285K ﹤0.01% 2799
2023
Q1
$67.3K Buy
46,088
+15,870
+53% +$30.4K ﹤0.01% 3025
2022
Q4
$49K Buy
+30,218
New +$69.6K ﹤0.01% 3057
2021
Q3
Sell
-28,137
Closed -$674K 3186
2021
Q2
$674K Buy
+28,137
New +$712K ﹤0.01% 1928

Squarepoint's KRON Position: Q2 2025 in Review

Squarepoint sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 113,607 shares — an estimated $93.7K sold.

Squarepoint first reported a position in KRON in Q2 2021 and held it in 9 quarters. The position peaked at $674K in Q2 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.

  • Squarepoint reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 113,607 Kronos Bio shares in Q2 2025, an estimated $93.7K.
  • Squarepoint first reported a position in Kronos Bio in Q2 2021 and held it in 9 quarters.
  • Squarepoint's Kronos Bio position peaked at $674K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.